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BACKGROUND: An early detection tool for EOC was constructed from analysis of biomarker expression data from serum collected
during the UKCTOCS.
METHODS: This study included 49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning
seven years pre-diagnosis. A logit model was trained by analysis of dysregulation of expression data of four putative biomarkers,
(CA125, phosphatidylcholine-sterol acyltransferase, vitamin K-dependent protein Z and C-reactive protein); by scoring the
speciﬁcity associated with dysregulation from the baseline expression for each individual.
RESULTS: The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC
set. Samples were analysed as a simulated annual screening programme, the algorithm diagnosed cases with >30% PPV 1–2 years
pre-diagnosis. For Type II cases (~80% were HGS) the algorithm classiﬁed 64% at 1 year and 28% at 2 years tDx as severe.
CONCLUSIONS: The panel has the potential to diagnose EOC one-two years earlier than current diagnosis. This analysis provides a
tangible worked example demonstrating the potential for development as a screening tool and scrutiny of its properties. Limits on
interpretation imposed by the number of samples available are discussed.
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BACKGROUND
The mortality from epithelial ovarian cancer (EOC), in the United
Kingdom was 4227 in 2016.1 In the UK the 5 year survival rate
drops from 90% for the 31% of cases that are diagnosed at stage I;
to 22% for the 49% of cases diagnosed at stage III or IV.1 The non-
speciﬁc nature of early EOC symptoms combined with the rarity of
the disease presents a major barrier to increasing rates of
detection of pre-clinical disease through the primary care setting.
Achieving a mortality reduction in EOC will require a screening
strategy capable of triggering intervention early enough to alter
the natural history of ovarian cancer.
In the context of a screening programme cancers may be
divided into indolent disease, patients with which tend to die of
other causes; treatable disease which if caught and managed
early may go into extended remission; and untreatable disease
amenable only to management and palliative care.2 A successful
screening programme must identify sufﬁcient numbers of
treatable cases for timely intervention, prior to their progression
to untreatable disease, to outweigh the cost and associated
harms of misdiagnosis of healthy individuals and unnecessary
treatment of indolent cases.
Two screening trials for EOC based on a multimodal strategy
involving the risk of ovarian cancer algorithm (ROCA),3 which
determines risk of ovarian cancer by detecting a sudden rapid
increase in CA125 level from baseline, have recently been
published: the United Kingdom Collaborative Trial of Ovarian
Cancer Screening (UKCTOCS) in low risk postmenopausal
women,4,5 and United Kingdom Familial Ovarian Cancer Screening
Study (UKFOCSS) in younger women with greater than 10%
lifetime risk based on family history or gene mutation in BRCA1/2.6
UKCTOCS demonstrated that a multimodal screening arm,
incorporating ROCA as a ﬁrst-line and transvaginal ultrasound as
a second-line test, was able to diagnose EOC at earlier stage than
the control arm whilst UKFOCSS demonstrated a stage shift in
cases diagnosed during screening programme versus cases
diagnosed over a year after screening stopped. At the time of
the initial UKCTOCS mortality report, although the early detection
by screening had not yielded a signiﬁcant reduction it demon-
strated a trend toward mortality beneﬁt and further follow up is
underway.4–6 The need remains for a screening strategy which
enables identiﬁcation of treatable EOC cases leading to a mortality
reduction.
A screening tool assigns a risk score to each participant. Every
possible demarcation threshold on the range of risk scores
represents a sensitivity-speciﬁcity pair which, combined with
disease prevalence, deﬁnes a positive predictive value and a
negative predictive value. Speciﬁcity and consequently positive
predictive value depend on the false positive rate. The numbers of
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false positives must be kept low to minimise the burden on health
services and healthy participants, but the majority of cases put to
the diagnostic test will be healthy so even a low error rate will
result in high absolute number of false positives. So, to make a
screening tool clinically viable the threshold score must be raised,
sacriﬁcing sensitivity for speciﬁcity until false positive numbers fall
to an acceptable level. The earliest most treatable cases are those
to which a tool is least sensitive, and which will be missed on the
ﬁrst pass. Detecting these cases requires sensitive tests that retain
the highest speciﬁcity enabling unambiguous diagnosis which
permits rapid initiation of clinical investigation and progress to
treatment. It is hoped that panels of complimentary biomarkers
may offer improved speciﬁcity over single biomarker tests, as non-
target diseases and benign conditions that dysregulate a single
biomarker should have minimal impact on other members of the
panel. Efforts to develop such a panel have not been successful
to date.
Here, we describe the development of a panel using data
from a subset of the prospectively collected serum samples
spanning up to 7 years time-to-diagnosis (tDx), obtained in the
course of the UKCTOCS trial. The 7-year tDx timespan permits
the discovery of biomarkers in serum collected prior to clinical
diagnosis of EOC; the period in which the asymptomatic but
treatable early forms of EOC occur. It has previously been
shown by a nested case-control study within the Prostate, Lung,
Colorectal and Ovarian Cancer (PLCO) screening trial that
a biomarker panel intended to supplement CA125 for EOC
diagnosis7 showed no improvement over CA125 alone, greater
than 6 months tDx.8 Recently proposed panels for EOC,9 and for
multiple cancers including EOC10 which were also developed in
clinically diagnosed cancers may suffer the same lack of
sensitivity in pre-clinical samples as demonstrated by the
PLCO study.
Our previously published work11,12 identiﬁed several biomarkers
for EOC. The following analysis presents a screening tool based on
the dysregulation of CA125 (uniprot: Q8WXI7) and the previously
described Vitamin K-dependent protein Z (PROZ, uniprot: P22891),
phosphatidylcholine-sterol acyltransferase (LCAT, uniprot: P04180)
and C-reactive protein (CRP, uniprot: P02741) against a pre-disease
baseline established for each individual patient. We demonstrate the
tool’s utility in a simulated annual screening programme providing
the basis to consider,13 with the addition of further validation
studies, how this may translate to a screening programme.
METHODS
Serum samples
UKCTOCS (International Standard Randomised Controlled Trial,
number ISRCTN22488978; ClinicalTrials.gov NCT00058032) was
given ethical approval (North West MREC 00/8/34). Trial design;
subject consent and ethical oversight; sample acquisition and
storage; and CA125 quantiﬁcation are available elsewhere3–6,14
see Table S1 for baseline characteristics of UKCTOCS participants
used within this study.
Samples were drawn from the multimodal arm of UKCTOCS
(50640 women) which, at the time this study was initiated, yielded
19 Type I and 109 Type II EOC cases. For this study 49 cases were
selected, comprising 30 Type II and 19 Type I (of which 10 were
borderline) EOC cases, for histological classiﬁcation see
Table S2.15,16 An additional 31 control women were selected with
no family history of EOC, no diagnosis of cancer during follow-up
and were matched by age, regional collection centre and
collection date to the Type II samples. The multiple serial serum
samples of these 80 women spanning up to 7 years prior to
diagnosis comprised a sample set of 482 distinct samples. Serum
levels for LCAT (Cloud Clone Corp., Wuhan, Hubei, China), CRP
(AbCam, Cambridge UK) and PROZ (AbCam) were available from
our previous described work.11,12
Scoring dysregulation
All data analysis were performed using R.17 As controls do not
have a time to diagnosis, for comparison with cases, samples from
the control women were allocated a tDx value so that the last
sample for each control was matched to the last sample from the
matched case allowing temporal alignment of controls and cases.
For each subject a baseline expression was estimated by taking
the mean of up to the three earliest samples available for each
subject drawn greater than 2 years tDx, this is the time interval
where cases behaved as controls. For each sample, from each
individual, absolute dysregulation from baseline was calculated.
Speciﬁcity thresholds for dysregulation for each marker were set
from the control data. For CA125, protein Z and LCAT this was so
that speciﬁcity <80% was assigned score 0, 80–90% 1, 90–95% 2,
95–97.5% 3, 97.5–98% 4, 98–99% 5 and >99% 6, for CRP it was set
to <70% 0, 70–80% 1, 80–90% 2, 90–95% 3, 95–99% 4, 99–99.5%
5, 99.5–99.9 6, and >99.9% 7 to give the model access to CRP’s
wider range of speciﬁcities. See Fig. 1 for graphical schematic of
the process.
Model training and performance
A logit model was ﬁtted to a training data set comprising Type II
EOC samples less than 2 years tDx and control samples excluding
three control women who developed cancer after study initiation.
This encompassed 28 control and 25 case subjects, providing 118
control samples and 50 case samples, resulting in a total of
168 samples.
Model coefﬁcients for each biomarker dysregulation score and
signiﬁcance of contribution to the model by the Wald test were
tabulated and the odds ratio describing the fold change in risk
associated with each increment in score was calculated for each
marker from the exponential of the coefﬁcient. Receiver operator
curve analysis was performed using the pROC package for R.18
Model cross-validation
To get an unbiased estimate of the predictive ability of the model
we used two established methods for sample sets of this size in
EOC research; Leave-one-out cross-validation and k-fold cross-
validation. Leave-one-out cross-validation has been shown to be
an efﬁcient alternative to having separate sample sets for
validation and it provides an unbiased estimate of the prediction
accuracy. Leave-one-out cross-validation was performed by
excluding each subject in turn from the training data set and re-
training the model to conﬁrm the stability of ﬁtted coefﬁcients.
Further k-fold cross-validation was performed by excluding a tenth
of the samples from the training set and re-training the model
again to conﬁrm the stability of ﬁtted coefﬁcients also enabling
ROC analysis of predictions made against the excluded set as
above. Standard deviations of the coefﬁcients were calculated for
each biomarker for each of these cross-validation strategies as a
measure of the stability of the model to restricted sample sets.
Simulated screening programme
The prospectively collected retrospectively analysed sample set
enabled simulation of EOC cases progression through a simpliﬁed
screening programme. The schema for the simulated programme
was based on a simpliﬁed version of the multimodal screening
arm of UKCTOCS.14 Since it is impossible to retrospectively apply
the protocol of that study with its repeat samples, ultrasound
scans and two-line strategy, a ﬁrst-line annual screen relying on a
blood test alone was simulated. The positive predictive value (PPV)
is the probability that a woman with a given risk score actually has
EOC which is the critical question for a clinician interpreting a test
result. Positive predictive values (PPV) were calculated from the
sensitivity-speciﬁcity pairs associated with each logit score
obtained from ROC analysis of EOC cases (Type I and II) <2-years
tDx vs all controls, combined with the prevalence of EOC in the
unscreened arm of the UKCTOCS trial.4 The latest sample prior to
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the annual screen cut-off 1–4-years tDx, were classiﬁed severe (S),
elevated (E) or intermediate (I) if they crossed PPV thresholds of
30%, 5% and 2.5% respectively, remaining samples were classiﬁed
normal (N). The classiﬁcations are analogous to those set in the
UKCTOCS trial, although with a much less sophisticated schema.
UKCTOCS set elevated (E) or intermediate (I) at PPV thresholds of
0.2% and 0.02857%, respectively and introduced a severe (S)
classiﬁcation at a PPV threshold of 20% for women returning for a
second line screen six weeks after an unsatisfactory ﬁrst-line
screen. This retrospective analysis cannot duplicate the conditions
of the larger prospective UKCTOCS trial in which the ROCA
algorithm was deployed in a multiple-step strategy incorporating
ultrasound scans, so a direct comparison is impossible. The
passage of EOC case samples through our simulated screening
programme was visualised with a river plot using the riverplot
package for R.19
Algorithm implementation
For a step by step description of the diagnostic algorithm
including look-up tables and model equations see Supplemental
methods. Brieﬂy; dysregulation scores are calculated as described
above for each of the four proteins; the equation of the model is
used to calculate the risk of ovarian cancer as a probability in the
range 0–1; ﬁnally, the risk classiﬁcation is determined from a table
of thresholds based on the positive predictive value associated
with the probability score.
RESULTS
Model parameters and performance
Summary statistics for the model are presented in Table 1 in which
the coefﬁcients are the parameters of the model; the p-values
indicated the signiﬁcance of each biomarker’s contribution to the
model by the Wald test; and the odds ratio describes the fold
change in risk associated with each step up in dysregulation score
for each biomarker. The marker, CA125, has the highest
signiﬁcance and makes the largest contribution to the odds ratio.
The three additional markers have similar odds ratios to each
other and the same order of magnitude as CA125 indicating they
make a valuable contribution to the model. ROC analysis of the
four biomarker panel model gave AUC 0.971 for EOC samples <1-
year tDx vs all controls, 0.920 for EOC samples <2-years tDx and
0.848 for EOC samples 1–2-years tDx see Fig. S1 for ROC curves.
Model cross-validation
To get an unbiased estimate of the predictive ability of the model
we used two established methods for sample sets of this size in
EOC research; leave-one-out cross-validation and k-fold cross-
validation.20–22 The standard deviations of the coefﬁcients from
these models are presented in Table 1 and have a mean of 10%,
indicating the coefﬁcients are not highly dependent on the
composition of the data set. Furthermore, each of the k-fold cross-
validation models furnishes a set of predictions on samples
excluded from the training set. ROC analysis of each of these test
sets gave a mean AUC of 0.957 for EOC samples <1-year tDx vs all
controls, 0.854 for EOC samples <2-years tDx and 0.774 for EOC
samples 1–2-years tDx see Fig. S2 for all ROC curves. Together
Table 1. Summary statistics for the model
Biomarker Coefﬁcient p-value Odds ratio LOO
Coeff SD
k-fold
cross-
validation
coeff SD
Intercept −3.5270 4.04e−11 0.0294 0.11 0.21
CA125 0.8217 6.45e−11 2.27 0.025 0.037
Protein Z 0.5345 8.72e−4 1.71 0.028 0.055
LCAT 0.3595 0.0211 1.43 0.024 0.059
CRP 0.3419 0.0260 1.41 0.043 0.065
Table showing, for each biomarker; the model coefﬁcients p-value
indicating signiﬁcance of contribution to the model by the Wald test;
the odds ratio, indicating the contribution of each additional step up on
the dysregulation score, for that biomarker, to the risk attribution of the
sample; leave-one-out (LOO) coefﬁcient standard deviation, showing the
stability of coefﬁcients to exclusion of each subject and the k-fold cross-
validation coefﬁcient standard deviation, showing stability of coefﬁcients
to excluding 10% of samples from the model in turn
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Fig. 1 Graphical schematic illustrating the algorithm for calculating dysregulation scores. For controls, baseline expression is calculated as the
mean of the earliest up to three samples more than 2 years tDx. Deviation from that baseline is then used to score biomarker dysregulation
either by up- or down-regulation based on speciﬁcity thresholds calculated from the controls
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these results demonstrate that in this sample set risk of ovarian
cancer is successfully modelled by the dysregulation of the panel
of protein biomarkers.
Sensitivity to Type I EOC cases
The four biomarker model was not trained against the Type I
EOC cases. The Type I EOCs have different histology and are less
aggressive than the Type II cases. Although not truly indepen-
dent in the sense that they derive from a separate study they
provide a challenge to the model trained against Type II cases.
Sensitivity of the model to the Type I cases shows the model is
not merely sensitive to the samples it was trained against
but is ﬁnding a real signal. ROC analysis gave AUC 0.891 for
EOC samples <1-year tDx vs all controls, 0.810 for EOC samples
<2-years tDx and 0.705 for EOC samples 1–2-years tDx see
Fig. S3 for all ROC curves. This shows the model trained in Type II
cases is able to diagnose both Type I and Type II EOC cases and
provides further conﬁdence the model is not over ﬁtted to the
training set.
Relationship between dysregulation scores and risk classiﬁcation
The model takes as input dysregulation scores 0–6 for CA125,
protein Z and LCAT and 0–7 for CRP. Considering risk classiﬁcation
attributed to different combinations of scores gives some insight
into how the model might behave in a screening programme. The
model input dysregulation scores would be as follows: {CA125;
PROZ; LCAT; CRP} and the model results given as {model score;
classiﬁcation N,I,E or S}.
If this panel offers an improvement on the current test which
is based on CA125, it would be expected to require contribution
from more markers than just CA125 to attribute the highest risk
scores. This is, in fact, the case as CA125 maximally dysregulated
with no other biomarkers included is {6,0,0,0}→{0.80, E}. To
attain a severe level classiﬁcation requires the contribution of
the maximum CA125 score with at least a single score on one of
the other markers {6,1,0,0}→{0.87, S}; {6,0,1,0}→{0.85, S}
{6,0,0,1}→{0.85, S}. The speciﬁcity of the test derives in part
from the requirement that risk be indicated by multiple markers,
by not detecting conditions known to elevate CA125 such as
endometriosis. For this sample set higher EOC risk estimates
generally resulted not from substantial dysregulation of a single
marker in the panel but from lesser dysregulation of multiple
panel members.
A successful panel would be expected to return a high risk of
EOC for moderate dysregulation scores on each of the biomarkers
in the panel. This is in fact the case as illustrated by the following
score combinations: { 2, 3, 3, 3}→{0.86, S}; { 3, 2, 3, 2}→{0.85, S}; and
{ 3, 3, 2, 2}→{0.86, S}. Thus, scores for each individual marker, with
speciﬁcity in the range of 90–97.5%, which would individually be
of no use in a screen; combine to form a test that is highly speciﬁc,
which retains sensitivity by drawing on the dysregulation of
multiple markers.
The potential of CRP, which is known to elevate in many
inﬂammatory events, to confound the screening tool with false
positives is limited by the way the model has been constructed.
The maximum score achievable by CRP dysregulation, with no
contribution from other members of the panel, is 7. This would
place an individual into the intermediate category {0,0,0,7}}→{0.24,
I}. Thus, elevation of CRP alone would not trigger urgent
intervention in a screening tool and the role of CRP in the model
is to enhance the risk score afforded by the other more speciﬁc
members of the panel.
Simulated screening programme
Assigning classiﬁcations severe (S), elevated (E), intermediate (I) or
normal (N) to samples depending on the PPV associated with the
sample enables simulation of a simpliﬁed annual screening
programme to enable consideration of how the screening tool
might be implemented in a screening programme. The progress
of individuals through the screening programme is visualised as a
river plot Fig. 2, which shows how classiﬁcation of samples from
women who developed Type I (not used to train model) or Type II
(used to train model) EOC evolve over time. The visualisation
shows the majority of women enter the simulated screening
programme at 4-years tDx with samples classiﬁed as normal and
subsequent samples show successively elevated risk towards
diagnosis. For Type II EOC the novel panel assigns 64 and 28% of
women to severe at 1 and 2-years tDx, respectively. For Type I EOC
the novel panel assigns 53 and 20% of women to severe, at 1
and 2-years tDx, respectively. The controls show a majority at
classiﬁcation normal over the 4-year period, however, some
controls (6 at year 4; 5 at year t3; 8 at year 2; 5 at year 1 tDx) were
seen with classiﬁcations other than normal over this time. Within
these samples there is a general pattern of risk estimates rising
and then falling again, suggesting a repeat testing strategy like
that deployed in UKCTOCS, might successfully eliminate them.
There is a single control case that is classiﬁed elevated at 4, 3 and
2 years tDx, but which then rises to severe 1-year tDx. This case is
more problematic and further investigation is required to under-
stand how frequent cases like this might be and if strategies are
available to deal with them.
A further visualisation of each individual EOC case increasing
risk classiﬁcation from the panel is shown in Fig. 3 enabling direct
comparison of risk scores for each woman. Cases are separated by
panel into Type I and Type II and grouped within panel by stage at
diagnosis. Coloured bars indicated the range of unbroken runs of
samples prior to diagnosis assigned incremental risk classiﬁcations
of at least normal (N), intermediate (I), elevated (E) or severe (S).
Survival time post diagnosis gives further clues to the aggressive-
ness of each cancer.
Type-I OC
4 3 2 1 4 3 2 1 4 3 2 1
Type-II OC
Years tDx
Control LevelLevel
S
E
I
N
20% 28% 68% 4%
S
E
I
N
4%7%
21% 10%
7% 7% 25% 14%
11%14%7%13%
53%
Fig. 2 River plots showing the progress of women’s risk classiﬁcation for years 4–1 tDx by taking the risk classiﬁcation of the latest sample
available prior to each annual screen cut-off. Plots based on the novel panel for Type I EOC cases (not used to train model) Type II EOC cases
(used to train model) and controls may be compared. Risk classiﬁcation elevates through intermediate (I), elevated (E) and severe (S) for the
novel panel for both Type I and Type II cases whereas the majority of control women remain classiﬁed as normal. Coloured lines indicate risk
classiﬁcations, normal (N) is green, intermediate (I) yellow, elevated (E) orange and severe (S) red
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The data also reveal features that add conﬁdence to the model’s
veracity. For example, Type II cases diagnosed at stage III are
generally given risk classiﬁcations E or S at longer lead times to
diagnosis than cases diagnosed at stages I and II, as would be
expected if the women had harboured undiagnosed tumours for
long enough for disease to reach the later stages. Over half the
cases diagnosed at stage III were given risk classiﬁcations of S 1–2-
years prior to diagnosis in the course of the trial, which invites
speculation into how clinical outcomes for these women might
have improved were the panel to have been available to them.
Of the two Type I case fatalities, one was not picked up prior to
diagnoses by the panel, however, the other was classiﬁed S by the
panel a year prior to diagnosis.
DISCUSSION
Ovarian cancer is a heterogeneous disease with tumour histology
identifying multiple distinct types with differing prognosis, genetic
markers and treatment regimens.23 It is possible that some of
these ovarian cancers are so aggressive they are essentially
untreatable and their successful identiﬁcation in a screening trial
may not reduce mortality. The challenge is to increase the
identiﬁcation of those treatable cases that do exist and to do so
before they progress and become untreatable.
In this study of prospectively collected and retrospectively
analysed samples, the tool presented above demonstrates an
improved performance over CA125 interpreted by ROCA alone for
early detection of ovarian cancer in the studied sample set. The
four protein model was able to offer up to a 1–2-year lead time in
diagnosis over that achieved for the cases in the UKCTOCS trail for
both Type I and Type II cases. A direct comparison to the ROCA
algorithm applied in the UKCTOCS trial and UKFOCSS study, is not
possible retrospectively and the smaller sample set used here is
likely to have resulted in an overestimation of the achievable PPVs.
However, the signal identiﬁed in the protein panel is certainly real
and warrants further investigation in independent sample sets
both in Type II and Type I EOCs.
The simulated screening programme shows the potential for
relatively subtle dysregulation, against patient baseline, of multi-
ple biomarkers in combination to return a sensitive and speciﬁc
assessment of EOC risk. Since either up- or down-regulation of
each marker contributed to risk estimation it may be better to
think of these makers not being directly mechanistically linked to
the initiation and progression of disease, but as independent polls
on dysregulation of several physiological systems. The degree and
direction of dysregulation being determined by multiple interact-
ing feedback mechanisms. There is a general lack of correlation
between biomarker scores indicating their independence whilst
the cases with low CA125 scores may still have high EOC
probability scores due to contributions from other biomarkers
showing how that independence contributes to sensitivity.
A caveat to the current model that should be borne in mind is
that the number of controls (141 samples from 31 women) may
underestimate the variability of expression of these proteins in
Type-I
IIIc
IIIc
IIIb
IIc
IIb
IIa
Ic
IIc
Ic
Ib
Ia
Type-II
–6 –4 –2 Dx
Years pre/post diagnosis
Panel Normal Elevated Death
SevereIntermediate
2 4 6 –6 –4 –2 Dx
Years pre/post diagnosis
2 4 6
Fig. 3 Each case is represented by a line from left to right across the graph, where disease-speciﬁc death was recorded post diagnosis this is
indicated by terminating the line with a cross. Cases are separated by panel into Type-I and Type-II EOC and grouped within panel by stage at
diagnosis. Coloured bars indicate the range of unbroken runs of samples prior to diagnosis, assigned incremental risk classiﬁcations of at least
normal (N), intermediate (I), elevated (E) or severe (S). High grade serous cases, the most frequent form of the disease responsible for the
highest mortality are indicated by a *
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women without ovarian cancer. Higher variability would reduce
the speciﬁcity of the test, reduce the PPV of risk estimates and
erode the conﬁdence in diagnosis. Speciﬁcity is critical at two
points in the analysis. The ﬁrst is where dysregulation from
baseline is scored by speciﬁcity thresholds derived from the
controls. The second is in the simulated screening programme
where PPV thresholds are set to classify subjects as normal,
intermediate, elevated or severe. One likely reason that this study
has underestimated variation is that there may be non-EOC
conditions, much more frequently occurring than EOC, but
sufﬁciently rare as to have been excluding from this control set,
that affect PROZ, LCAT and CRP levels just endometriosis and the
menstrual cycle do for CA125.24,25 Analysis of the longitudinal
behaviour of these proteins in a much larger cohort of control
women is required to obtain more precise estimates of speciﬁcity
and PPV. In mitigation of this, however, the most concerning
member of the panel in this regard (CRP) returns only
intermediate risk if dysregulated alone. This indicates robustness
to confounding conditions. Despite the important caveats above
the investigation of the relationship between possible combina-
tions of dysregulation score and risk estimate indicate that
elevation of risk on a single biomarker, even CA125, does not
return the highest risk estimates.
The strategy of developing a biomarker panel in the context of
a simulated screening (Figs. 2 and 3) programme based on the
UKCTOCS trial has focused analysis on the clinically critical positive
predictive value, which has further enabled risk estimates from the
tool to be related to potential care pathways. The panel and
associated model developed pursuing this strategy is able to
detect EOC in samples drawn from women 1–2-years prior to their
diagnosis in the course of the UKCTOCS trial. This time period is
expected to contain a high proportion of cases at a treatable stage
where patients may beneﬁt from a 90% rather than a 22% 5-year
survival rate which would be of substantial clinical utility.
This analysis from the concept of taking markers as indepen-
dent polls on physiological dysregulation (indicative of disease),
through to a simulated screening programme, provides not just an
abstracted statistical relationship between marker and disease
status; but a tangible worked example accessible to oncologists.
This study alone is not sufﬁcient to justify deployment as a
screening tool given the limitations of the analysis we have
highlighted. The new panel does, however, have sufﬁcient
potential to justify a larger scale validation study and conﬁrms
the presence of EOC detecting signal from protein biomarker
panels in early asymptomatic EOC.
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